The EORTC Gastrointestinal Tract Cancer Group meeting will be held as a hybrid event in Brussels, Belgium on 6 May 2022 from 11:00-18:15 CEST. It is only open to individual or site staff members of the group. The meeting will be followed by a dinner. Registrations for the meeting are now closed. Please send an email [...]

DEERFIELD, Ill., September 5, 2018 – Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced the launch of the second phase of its partnership with the European Organisation for Research and Treatment of Cancer (EORTC). As a leader in Corporate Social Responsibility, Walgreens Boots Alliance is setting the pace on some of the most important health [...]

The EORTC Gastrointestinal Cancer Group (GITCG) is launching its young investigator’s (YI) programme for the term 2018 to 2020. The aim of the YI programme is to develop a platform for innovative ideas, mentor future leaders of GI oncology and provide hands-on training for conducting international cancer research. The main requirements to be part of [...]

The next generation sequencing service provider for SPECTA, 14M Genomics, has decided to close down operations due to withdrawal of funding from Syncona LLP, the sole investor of 14M Genomics. At this time, more than 850 patients have been included in SPECTAcolor and more than 120 patients have been included in SPECTAlung. More than 500 [...]

Venue Thursday, 20th of October 2016 Topic: EORTC GITCG Task Forces meeting and SPECTAcolor steering committee Venue: Centrum Onkologii-Instytyt, Roentgena 5, Warsaw Friday, 21st of October 2016 Topic: EORTC GITCG Groups Meeting Venue: Novotel hotel, ul Marszalkowska 94/98, Warsaw Saturday, 22nd of October 2016 Topic: Scientific meeting Venue: Novotel hotel, ul Marszalkowska 94/98, Warsaw Registration [...]

SAN DIEGO and BRUSSELS--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, and the European Organisation for Research and Treatment of Cancer (EORTC) today announced that they will collaborate via EORTC’s Screening Patients for Efficient Clinical Trial Access (SPECTA) biomarker screening initiative to identify patients who harbor a gene rearrangement to NTRK1, NTRK3, ROS1 [...]